<p>拜耳公司（Bayer AG ((BAYRY)）已召开第三季度财报电话会议。以下是会议的主要亮点。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的_ETF_ AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
<p>拜耳公司最新的财报电话会议描绘了其制药部门的强劲增长，得益于成功的产品发布。然而，公司也面临着重大的财务挑战、诉讼风险和市场困难，尤其是在其消费者健康部门。</p>
<h2>制药部门增长</h2>
<p>拜耳公司的制药部门展示了令人印象深刻的增长，Nubeqa 的销售同比增长 60%，Kerendia 的销售增长近 80%。这一增长主要得益于美国和中国的强劲表现，突显了该部门成功的市场渗透和产品接受度。</p>
<h2>Beyonttra 的快速接受</h2>
<p>Beyonttra 是一种心血管治疗药物，在德国取得了显著成功，约占新品牌处方市场份额的 50%。这标志着心血管治疗药物的快速接受，突显了该产品强大的市场吸引力和进一步增长的潜力。</p>
<h2>作物科学玉米部门增长</h2>
<p>作物科学部门报告玉米销售增长 22%，这归因于美国的种植面积扩大和拉丁美洲季节的强劲开局。这一增长突显了该部门在扩大市场份额和利用有利农业条件方面的战略重点。</p>
<h2>Lynkuet 获得 FDA 批准</h2>
<p>拜耳的新产品 Lynkuet 获得 FDA 批准，并将在本月进入美国市场。这一批准是拜耳的重要里程碑，因为它继续扩展其产品组合并加强在制药市场的地位。</p>
<h2>自由现金流和债务担忧</h2>
<p>拜耳报告自由现金流为负 8 亿欧元，净金融债务为 327 亿欧元。这些数字突显了公司面临的财务挑战，迫切需要战略性财务管理来解决现金流和债务问题。</p>
<h2>消费者健康市场挑战</h2>
<p>消费者健康部门面临着特别是在美国和中国的市场环境挑战，导致对 2025 年的销售增长预期进行了修订。尽管面临这些挑战，拜耳仍致力于保持 23% 至 24% 的 EBITDA 利润率。</p>
<h2>诉讼和监管挑战</h2>
<p>拜耳继续面临未解决的草甘膦诉讼和监管挑战，例如 Movento 在欧洲的许可证到期，影响销售。这些问题突显了拜耳必须应对的复杂监管环境。</p>
<h2>Eylea 销售下降</h2>
<p>Eylea 的销售在第三季度下降了 11%，主要由于日本和加拿大的显著价格压力。这一下降突显了制药市场的竞争压力和定价挑战。</p>
<h2>前瞻性指导</h2>
<p>展望未来，拜耳报告本季度和年初至今的货币和组合调整销售略有增长。核心每股收益增长 7%，达到 4.29 欧元，与预期一致。尽管作物科学部门和消费者健康部门面临挑战，拜耳对实现其升级后的 2025 年指导持乐观态度，主要得益于 Beyonttra 和 Lynkuet 等新产品的增长。</p>
<p>总之，拜耳公司的财报电话会议反映出公司在增长机会和财务挑战的复杂环境中航行。虽然制药部门表现强劲，但公司必须解决财务和监管障碍，以维持其势头。投资者将密切关注拜耳的战略举措，以克服这些挑战并利用新的市场机会。</p>

BAYN

<p>拜耳公司第三季度的财报电话会议强调了其制药部门的强劲增长，主要得益于 Nubeqa 和 Kerendia 的强劲销售。Beyonttra 在德国市场上获得了显著的市场份额。农作物科学部门的玉米销售增长了 22%。然而，拜耳面临财务挑战，包括负自由现金流和高负债、消费健康领域的市场困难以及诉讼风险。尽管存在这些问题，拜耳对实现 2025 年的指导目标仍持乐观态度，新的产品如 Beyonttra 和 Lynkuet 为其提供了支持</p>

<p>Bayer AG ((BAYRY)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>拜耳公司（Bayer AG ((BAYRY)）已召开第三季度财报电话会议。以下是会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的_ETF_ AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
</div><p>Bayer AG’s latest earnings call painted a picture of robust growth in its Pharmaceuticals division, buoyed by successful product launches. However, the company also faces significant financial challenges, litigation risks, and market difficulties, particularly in its Consumer Health segment.</p>
<div class="lb-trans"><p>拜耳公司最新的财报电话会议描绘了其制药部门的强劲增长，得益于成功的产品发布。然而，公司也面临着重大的财务挑战、诉讼风险和市场困难，尤其是在其消费者健康部门。</p>
</div><h2>Pharmaceuticals Division Growth</h2>
<div class="lb-trans"><h2>制药部门增长</h2>
</div><p>The Pharmaceuticals division of Bayer AG showcased impressive growth, with Nubeqa sales increasing by 60% year-over-year and Kerendia sales rising by nearly 80%. This growth was primarily driven by strong performances in the U.S. and China, highlighting the division’s successful market penetration and product acceptance.</p>
<div class="lb-trans"><p>拜耳公司的制药部门展示了令人印象深刻的增长，Nubeqa 的销售同比增长 60%，Kerendia 的销售增长近 80%。这一增长主要得益于美国和中国的强劲表现，突显了该部门成功的市场渗透和产品接受度。</p>
</div><h2>Record Uptake of Beyonttra</h2>
<div class="lb-trans"><h2>Beyonttra 的快速接受</h2>
</div><p>Beyonttra, a cardiovascular treatment, achieved remarkable success in Germany, capturing around 50% market share in new to brand prescriptions. This marks one of the fastest uptakes for a cardiovascular treatment, underscoring the product’s strong market appeal and potential for further growth.</p>
<div class="lb-trans"><p>Beyonttra 是一种心血管治疗药物，在德国取得了显著成功，约占新品牌处方市场份额的 50%。这标志着心血管治疗药物的快速接受，突显了该产品强大的市场吸引力和进一步增长的潜力。</p>
</div><h2>Crop Science Corn Segment Growth</h2>
<div class="lb-trans"><h2>作物科学玉米部门增长</h2>
</div><p>The Crop Science division reported a 22% increase in corn sales, attributed to acreage expansion in the U.S. and a robust start to the Latin American season. This growth highlights the division’s strategic focus on expanding its market presence and capitalizing on favorable agricultural conditions.</p>
<div class="lb-trans"><p>作物科学部门报告玉米销售增长 22%，这归因于美国的种植面积扩大和拉丁美洲季节的强劲开局。这一增长突显了该部门在扩大市场份额和利用有利农业条件方面的战略重点。</p>
</div><h2>FDA Approval of Lynkuet</h2>
<div class="lb-trans"><h2>Lynkuet 获得 FDA 批准</h2>
</div><p>Lynkuet, a new product from Bayer, received FDA approval and is set to enter the U.S. market this month. This approval is a significant milestone for Bayer, as it continues to expand its product portfolio and strengthen its position in the pharmaceutical market.</p>
<div class="lb-trans"><p>拜耳的新产品 Lynkuet 获得 FDA 批准，并将在本月进入美国市场。这一批准是拜耳的重要里程碑，因为它继续扩展其产品组合并加强在制药市场的地位。</p>
</div><h2>Free Cash Flow and Debt Concerns</h2>
<div class="lb-trans"><h2>自由现金流和债务担忧</h2>
</div><p>Bayer reported a negative free cash flow of EUR 800 million, with net financial debt standing at EUR 32.7 billion. These figures highlight the financial challenges the company faces, necessitating strategic financial management to address cash flow and debt concerns.</p>
<div class="lb-trans"><p>拜耳报告自由现金流为负 8 亿欧元，净金融债务为 327 亿欧元。这些数字突显了公司面临的财务挑战，迫切需要战略性财务管理来解决现金流和债务问题。</p>
</div><h2>Consumer Health Market Challenges</h2>
<div class="lb-trans"><h2>消费者健康市场挑战</h2>
</div><p>The Consumer Health segment encountered a challenging market environment, particularly in the U.S. and China, leading to a revised sales growth expectation for 2025. Despite these challenges, Bayer remains committed to maintaining an EBITDA margin between 23% and 24%.</p>
<div class="lb-trans"><p>消费者健康部门面临着特别是在美国和中国的市场环境挑战，导致对 2025 年的销售增长预期进行了修订。尽管面临这些挑战，拜耳仍致力于保持 23% 至 24% 的 EBITDA 利润率。</p>
</div><h2>Litigation and Regulatory Challenges</h2>
<div class="lb-trans"><h2>诉讼和监管挑战</h2>
</div><p>Bayer continues to grapple with unresolved glyphosate litigation and regulatory challenges, such as the expiration of Movento’s Europe license, impacting sales. These issues underscore the complex regulatory landscape Bayer must navigate.</p>
<div class="lb-trans"><p>拜耳继续面临未解决的草甘膦诉讼和监管挑战，例如 Movento 在欧洲的许可证到期，影响销售。这些问题突显了拜耳必须应对的复杂监管环境。</p>
</div><h2>Eylea Sales Decline</h2>
<div class="lb-trans"><h2>Eylea 销售下降</h2>
</div><p>Eylea sales experienced an 11% decline in Q3, primarily due to significant pricing pressure in Japan and Canada. This decline highlights the competitive pressures and pricing challenges in the pharmaceutical market.</p>
<div class="lb-trans"><p>Eylea 的销售在第三季度下降了 11%，主要由于日本和加拿大的显著价格压力。这一下降突显了制药市场的竞争压力和定价挑战。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Looking ahead, Bayer reported a slight increase in currency and portfolio-adjusted sales for the quarter and year-to-date. Core earnings per share rose by 7% to EUR 4.29, aligning with projections. Despite challenges in the Crop Science division and Consumer Health segment, Bayer remains optimistic about meeting its upgraded 2025 guidance, driven by growth from new products like Beyonttra and Lynkuet.</p>
<div class="lb-trans"><p>展望未来，拜耳报告本季度和年初至今的货币和组合调整销售略有增长。核心每股收益增长 7%，达到 4.29 欧元，与预期一致。尽管作物科学部门和消费者健康部门面临挑战，拜耳对实现其升级后的 2025 年指导持乐观态度，主要得益于 Beyonttra 和 Lynkuet 等新产品的增长。</p>
</div><p>In summary, Bayer AG’s earnings call reflects a company navigating a complex landscape of growth opportunities and financial challenges. While the Pharmaceuticals division shows strong performance, the company must address financial and regulatory hurdles to sustain its momentum. Investors will be keenly watching Bayer’s strategic moves to overcome these challenges and capitalize on new market opportunities.</p>
<div class="lb-trans"><p>总之，拜耳公司的财报电话会议反映出公司在增长机会和财务挑战的复杂环境中航行。虽然制药部门表现强劲，但公司必须解决财务和监管障碍，以维持其势头。投资者将密切关注拜耳的战略举措，以克服这些挑战并利用新的市场机会。</p>
</div>

拜耳公司财报电话会议：在挑战中实现增长